Table 3. Demographic and histologic data for major subgroups of non-small cell lung carcinoma (n=438).
| AC (n=213) | SCC (n=135) | Other NSCLC (n=90) |
p | ||||
|---|---|---|---|---|---|---|---|
| n | (%) | n | (%) | n | (%) | ||
| Sex | <0.001a | ||||||
| Male | 111 | (52.1) | 109 | (80.7) | 57 | (63.3) | |
| Female | 102 | (47.9) | 26 | (19.3) | 33 | (36.7) | |
| Age | ns | ||||||
| Median (range) | 67 | (32-84) | 69 | (24-84) | 66 | (44-85) | |
| Tumor size | <0.001b | ||||||
| Median (range) | 30 | (10-130) | 40 | (7-110) | 40 | (12-165) | |
| Histologic grade | <0.001a | ||||||
| Well differentiated | 33 | (15.5) | 6 | (4.4) | 0 | (0) | |
| Mod. differentiated | 82 | (38.5) | 63 | (46.7) | 4 | (4.4) | |
| Poorly differentiated | 97 | (45.5) | 66 | (48.9) | 12 | (13.3) | |
| Undifferentiated | 1 | (0.5) | 0 | (0) | 74 | (82.2) | |
| Adenocarcinoma subtype | |||||||
| MIA | 2 | (0.9) | |||||
| Lepidic | 20 | (9.4) | |||||
| Acinar | 82 | (38.5) | |||||
| Papillary | 20 | (9.4) | |||||
| Micropapillary | 3 | (1.4) | |||||
| Solid | 81 | (38.0) | |||||
| Mucinous | 5 | (2.3) | |||||
| BVI | 0.029a | ||||||
| Absent | 149 | (70.0) | 111 | (82.2) | 70 | (77.8) | |
| Present | 64 | (30.0) | 24 | (17.8) | 20 | (22.2) | |
| LVI | 0.023a | ||||||
| Absent | 158 | (74.2) | 112 | (83.0) | 78 | (86.7) | |
| Present | 55 | (25.8) | 23 | (17.0) | 12 | (13.3) | |
| Necrosis | <0.001a | ||||||
| Absent | 94 | (44.1) | 9 | (6.7) | 7 | (7.8) | |
| Present | 119 | (55.9) | 125 | (92.6) | 83 | (92.2) | |
| Inflammation | 0.003a | ||||||
| Mild/moderate | 192 | (90.1) | 104 | (77.0) | 73 | (81.1) | |
| Severe | 21 | (9.9) | 31 | (23.0) | 17 | (18.9) | |
| Pleural invasion | 0.031a | ||||||
| No | 149 | (70.0) | 111 | (82.2) | 64 | (71.1) | |
| Yes | 64 | (30.0) | 24 | (17.8) | 26 | (28.9) | |
| Tumor stage | ns | ||||||
| I | 90 | (42.3) | 62 | (45.9) | 36 | (40.0) | |
| II | 72 | (33.8) | 51 | (37.8) | 32 | (35.6) | |
| III | 42 | (19.7) | 20 | (14.8) | 19 | (21.1) | |
| IV | 5 | (2.3) | 2 | (1.5) | 0 | (0) | |
| Unknown | 4 | (1.9) | 0 | (0) | 3 | (3.3) | |
| Sites of metastasis during follow-up | |||||||
| Liver | 19 | (8.9) | 9 | (6.7) | 13 | (14.8) | ns |
| Adrenal | 16 | (7.5) | 0 | (0.0) | 7 | (5.3) | 0.004 |
| Brain | 47 | (22.1) | 8 | (6.0) | 18 | (20.2) | <0.001 |
| Bone | 36 | (16.9) | 13 | (9.7) | 13 | (14.6) | ns |
| Skin | 7 | (3.3) | 4 | (3.0) | 2 | (2.2) | ns |
| Other | 28 | (13.1) | 9 | (6.7) | 10 | (11.2) | ns |
| Status at latest observation | 0.016a | ||||||
| Dead from lung cancer | 94 | (44.1) | 43 | (31.9) | 40 | (44.4) | |
| Dead with lung cancer | 8 | (3.8) | 3 | (2.2) | 4 | (4.4) | |
| Dead from other causes | 44 | (20.6) | 53 | (39.2) | 23 | (25.6) | |
| Alive with disease recurrence | 7 | (3.3) | 0 | (0) | 1 | (1.1) | |
| Recovered | 60 | (28.2) | 36 | (26.7) | 22 | (24.4) | |
| Smoking history | 0.021 | ||||||
| Never | 20 | (9.4) | 1 | (0.7) | 3 | (3.3) | |
| Former | 76 | (35.7) | 56 | (41.8) | 34 | (37.8) | |
| Current | 116 | (54.5) | 75 | (56.0) | 51 | (56.7) | |
| Unknown | 1 | (0.5) | 2 | (1.5) | 2 | (1.1) | |
| Adjuvant radiotherapy | ns | ||||||
| No | 180 | (84.5) | 119 | (88.1) | 77 | (85.6) | |
| Yes | 30 | (14.1) | 14 | (10.4) | 12 | (13.3) | |
| Unknown | 3 | (1.4) | 2 | (1.5) | 1 | (1.1) | |
| Adjuvant chemotherapy | ns | ||||||
| No | 159 | (74.6) | 103 | (76.3) | 69 | (76.7) | |
| Yes | 51 | (23.9) | 30 | (22.2) | 20 | (22.2) | |
| Unknown | 3 | (1.4) | 2 | (1.5) | 1 | (1.1) | |
aPearson’s chi-square test across the three histological subgroupsbIndependent samples Kruskal-Wallis test across the three histological subgroups
AC, adenocarcinoma; SCC, squamous cell carcinoma; n, number of patients; BVI, blood vessel invasion; LVI, lymphatic vessel invasion; ns, not significant